Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group.
about
Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degenerationAn overview of clinical and commercial impact of drug delivery systemsLiposomes and nanotechnology in drug development: focus on ocular targetsTreatment of CMV retinitis with intravitral ganciclovir in the HAART eraMedical management of human immunodeficiency virus infection.Drug delivery to the posterior segment of the eye for pharmacologic therapy.Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon's implant in the rat.Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerValganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients.New developments in sustained release drug delivery for the treatment of intraocular diseaseOptimal management of cytomegalovirus retinitis in patients with AIDS.Therapeutic developments in cytomegalovirus retinitis.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theContact dermatitis from topical antiviral drugs.Uveitis: what do we know and how does it help?Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy.Management of CMV disease in HIV infection.Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.Cytomegalovirus (CMV) resistance to antivirals.Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.Emerging drugs for ophthalmic diseases.Emerging trends in infections among renal transplant recipients.Ocular association of HIV infection in the era of highly active antiretroviral therapy and the global perspective.Ganciclovir implant in the treatment of cytomegalovirus retinitis.Drug delivery from ocular implants.Developments in dosing aids and adherence devices for glaucoma therapy: current and future perspectives.Novel approaches to retinal drug delivery.Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic managementSilicone-acyclovir controlled release devices suppress primary herpes simplex virus-2 and varicella zoster virus infections in vitroOphthalmic drug delivery: development and regulatory considerations.Drug delivery options for the treatment of ocular inflammation.Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.CMV retinopathy in the antiretroviral therapy era: prevention, diagnosis, and management.Advances in the understanding of retinal drug disposition and the role of blood-ocular barrier transporters.Local therapy for cytomegalovirus retinitis.Applications of polymers in intraocular drug delivery systemsCanadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDS.Cytomegalovirus and the eye.Incidence Rate and Risk Factors for Contralateral Eye Involvement among Patients with AIDS and Cytomegalovirus Retinitis Treated with Local Therapy.
P2860
Q24243503-EA743106-B673-4A3F-A84B-C2298C698F17Q27007143-1778E861-BF9B-465D-86F7-C6FC289F332AQ27687657-82FB2E73-A32C-4DBB-99AB-6D7EF4616324Q28262771-95B87391-4351-451E-8A00-1F4A1A502D38Q30371489-BA55F790-895D-46C2-BD82-71D27624FE4EQ30478379-F8C79E3E-EF4C-4F8C-9C76-441C9A4FD760Q33523210-1C948414-F8DD-4741-AF66-5B33BFBE31E3Q33625721-DFA666AA-9C0D-488D-9119-96CEE42382D3Q33650105-128CF6D6-2E34-4C54-B822-E0BFD4E42C1DQ33715300-D7E8EE4E-20F3-492C-AB81-92B6E7CE4CFFQ33760311-39C1014E-5BA5-4B91-9D20-7C652FF31C51Q33819834-559CD58C-4028-4302-AEFD-5BA07CC223F9Q34074692-5A86297D-D869-45BD-8165-29DE05BB1724Q34212799-853AD043-B1F2-461D-8343-1C254D3B0752Q34216587-FC8CFE4E-3632-490B-8AB6-2CEB844F5860Q34243944-78A38694-3366-4BC6-AB8E-E19CFC22082AQ34590916-65B87FE5-F3C0-4EE1-A5B8-E314080155ADQ34660073-3A539A61-B061-413D-A863-436C3FCD0379Q34670354-6A3770A9-6DC2-477B-9A50-B230E0E16F63Q34722194-DE4D332B-A68F-45DB-BF91-E63FD8FC6D4FQ35557331-609F4329-E90D-4818-B032-AE7DF46A8CA6Q35581180-50DA4F79-7223-49E1-9B70-200AD8B14ACFQ35917332-BF3ACDA1-D9C1-4F93-A3C9-1508DD3A7E8BQ36149139-72CF1015-C2D1-4754-864B-12954CDF3B83Q36315123-7B7A73DE-E23F-4745-8387-0AE5E418ABDFQ36409058-68EC53D4-4960-4739-B0B4-7F3E65260211Q36759536-5350C807-0FA8-4D61-9706-209B1C9499BFQ36903801-C2453719-CB59-4256-8669-331E011EEE5FQ36920430-6ECF7D44-99D0-4CD1-A6B0-0EC679FFAB36Q37105722-4C259A8C-454B-4AFA-8414-79C0306A4C6DQ37395756-676C4C93-DBA8-4934-A30A-7BCBC313B471Q37810939-EBB8AF4D-C65A-446A-8222-C058B4C83C01Q37951633-E7E05F6B-624F-42BA-89E4-EAC46B63E0BFQ38017949-A216FCED-479B-4ABC-BBE2-A871AF4A6815Q38104396-EE60C93D-BB5B-4157-A87E-57C3F3D74E04Q38553191-BBACB6DF-E268-4E0B-ACFB-493ACD852186Q38904930-316734D6-2D23-462C-A349-B24A945AD7E2Q40669533-0EF740D9-F13D-443F-8F8F-14B171FD6B1CQ40847708-3744289D-9D4F-49AF-B981-BDD175EA5994Q41022017-62938A9E-E035-47CC-AECF-87AE2947734A
P2860
Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Treatment of cytomegalovirus r ...... nciclovir Implant Study Group.
@en
Treatment of cytomegalovirus r ...... nciclovir Implant Study Group.
@nl
type
label
Treatment of cytomegalovirus r ...... nciclovir Implant Study Group.
@en
Treatment of cytomegalovirus r ...... nciclovir Implant Study Group.
@nl
prefLabel
Treatment of cytomegalovirus r ...... nciclovir Implant Study Group.
@en
Treatment of cytomegalovirus r ...... nciclovir Implant Study Group.
@nl
P2093
P1476
Treatment of cytomegalovirus r ...... nciclovir Implant Study Group.
@en
P2093
P356
10.1056/NEJM199707103370203
P407
P577
1997-07-01T00:00:00Z